share_log

Spectral Receives UKCA Authorization For Burn Indication Expected Commercialization In H2 2024

Spectral Receives UKCA Authorization For Burn Indication Expected Commercialization In H2 2024

Spectral 获得 UKCA 烧伤指示授权,预计将于 2024 年下半年实现商业化
Benzinga ·  02/22 08:03

Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that its predictive software DeepView AI-Burn has obtained the final stage of UK Conformity Assessed (UKCA) authorization, for aiding in burn wound diagnosis in the United Kingdom.

Spectral AI, Inc.(纳斯达克股票代码:MDAI)(“Spectral AI” 或 “公司”)是一家专注于医学诊断以实现更快、更准确的伤口护理治疗决策的人工智能(AI)公司,今天宣布,其预测软件DeepView AI-Burn已获得英国合规评估(UKCA)的最后阶段授权,用于帮助英国进行烧伤诊断。

"I am delighted to announce this achievement in our Company's evolution. The completion of this milestone will allow us to sell our DeepView System in the UK and we expect to swiftly deploy six devices in the UK for customer evaluation and to begin generating revenue in the second half of this year." said Wensheng Fan, the Company's Chief Executive Officer. "In addition, this regulatory authorization opens up the ability to expand partnerships with regions such as the Middle East that recognize the UKCA authorization." Revenue from commercialization in the UK in 2024 represents an addition to the $28 million revenue guidance previously communicated by the Company.

“我很高兴地宣布我们公司发展过程中取得的这一成就。这一里程碑的完成将使我们能够在英国销售我们的DeepView系统,我们预计将迅速在英国部署六台设备进行客户评估,并将在今年下半年开始创收。” 该公司首席执行官范文生说。“此外,该监管授权为扩大与承认UKCA授权的中东等地区的合作伙伴关系开辟了能力。”2024年英国商业化收入是对该公司先前公布的2,800万美元收入指引的补充。

The DeepView System wound imaging device uses AI-enabled algorithms analyzing real-life patient wounds that assess clinically validated data points to distinguish between healthy and damaged tissue within seconds, unlike the current standard of care, which requires up to three to four weeks of evaluation. The technology establishes a high level of accuracy, 92%, in discerning whether tissue will heal naturally or necessitate surgical intervention, a process that is currently done by clinicians relying on visual observation and resulting in clinical judgement between only 50% to 75% accuracy.
"The current practice of prolonged and expensive observation with open wounds that risk infection before deciding on the best management of care is outdated," said Prof. Paul Chadwick, Spectral AI's Executive Vice President of the Company's United Kingdom subsidiary. "This protracted decision process burdens the patient as well as the healthcare system with unnecessary hospitalization time. The authorization of the DeepView System could effectively obviate the need for these long observation periods, accelerating the way we manage burn wounds in the UK."

DeepView System伤口成像设备使用基于人工智能的算法来分析现实生活中的患者伤口,评估经过临床验证的数据点,在几秒钟内区分健康和受损组织,这与目前的护理标准不同,目前的护理标准需要长达三到四周的评估。该技术在辨别组织是自然愈合还是需要手术干预方面确立了很高的准确度,为92%,这一过程目前由临床医生依靠视觉观察来完成,因此临床判断的准确性仅为50%至75%。
Spectral AI英国子公司执行副总裁保罗·查德威克教授说:“在决定最佳护理管理之前,对有感染风险的开放性伤口进行长时间且昂贵的观察的做法已经过时了。”“这种漫长的决策过程给患者和医疗保健系统带来了不必要的住院时间。DeepView系统的授权可以有效地避免长时间的观察,从而加快我们在英国管理烧伤的方式。”

UKCA marking is a certification system established by the UK government to ensure that products meet specified standards for sale in the UK (England, Wales, and Scotland). The DeepView AI-Burn is currently indicated for individuals aged eighteen and above. The Company aims to extend its technology to benefit pediatric populations and is continuing to initiate case studies and case series with surgeons at leading burn centers.

UKCA 标志是英国政府建立的认证体系,旨在确保产品符合在英国(英格兰、威尔士和苏格兰)销售的特定标准。DeepView AI-Burn 目前适用于十八岁及以上的个人。该公司旨在扩展其技术,使儿童受益,并将继续与主要烧伤中心的外科医生一起启动案例研究和案例系列。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发